tarceva

Tarceva approved in US and EU for first-line treatment of non-small-cell lung cancer after chemotherapy.

特罗凯在美国和欧盟被批准用于非小细胞肺癌化疗后一线治疗。

In pancreatic cancer trials, the incidence of these events was 2.5% in the Tarceva group and 0.4% in the placebo group.

胰腺癌试验中，特罗凯组中发生这些事件的比率为2.5%，安慰剂组中此比率为0.4%。

The drug Tarceva, which costs about $3, 500 a month, was approved as a treatment for pancreatic cancer because it improved survival by 12 days.

比如使用特赛瓦抗癌药（Tarceva），一个月的花费大概是3500美元，但就因为它被证实可以延长患者12天的生命而被批准为胰腺癌的治疗用药。

Infrequent cases of serious Interstitial Lung Disease (ILD) -like events, including fatalities, have been observed in patients receiving Tarceva.

接受特罗凯治疗的患者中观察到罕见的严重的间质性肺病(ILD)疑似事件，甚至导致死亡。